EMA continues to monitor very rare blood clots with low blood platelets that occurred after vaccination with Vaxzevria (previously COVID-19 Vaccine AstraZeneca).
In line with a request from the EU’s Commissioner for Health and Food Safety following a meeting of EU Health Ministers, EMA is undertaking a review of vaccination data and data on disease epidemiology (including infection rates, hospitalisations, morbidity and mortality).
The review by EMA’s human medicines committee (CHMP) will enable authorities to put the risks of Vaxzevria into the context of the benefits of ongoing vaccination campaigns. The Committee will also consider whether to update recommendations for a second dose of Vaxzevria in those who have already received the first dose.
EMA considers the overall benefits of the vaccine continue to outweigh the risks in people being vaccinated. The CHMP’s review will support ongoing national vaccination campaigns in their decisions on how to optimally deploy the vaccine
As for all vaccines, EMA will continue to monitor Vaxzevria’s safety and effectiveness and provide the public with the latest information.